Dr. Ramachandran “TR” Thirucote is a founding Chair and CEO of TesoRx Pharma, LLC and its affiliate, LIPAC Oncology, Inc., clinical stage companies that are focused on delivering innovative, optimized therapies in areas of unmet medical needs. Each of the companies leverage a novel drug delivery platform technology to target a range of treatments including urology and oncology. TR has several decades of experience in the design, development and launch of innovative therapeutics and dosage forms covering all dosage forms such as solid orals, parenteral and topicals. At Roxro Pharma, LLC, a leading edge virtual pharma company model, TR was instrumental is design development and NBA launch of SprixTM, a novel nasal spray drug-device combination for a non-opioid for post-operative surgical pain. At SRI International (formerly Stanford Research Institute), TR pioneered a contract pharma model (CRO), that encompassed government contracts with commercial pharma product development, setting the table for the successful establishment of several start up biotech and pharma companies across the country. He was also very successful as a PI and helped establish ongoing contracts with NIH affiliated institutes such as NIAID and NCI. At Agouron Pharma (now Pfizer), TR led the oncology portfolio development, moving the company’s first lead molecule in to clinical trials. As a scientist at Thermedics (now a division of Thermo Fischer Scientific), TR was responsible for the development of a novel polymeric wound dressing under a DOD contract, advised by Dr. R. Langer (MIT).
